Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Thoracic 3Gynecologic 3Gastrointestinal 3Lymphoid 2Genitourinary 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Melanoma 864Lymphoma, T-Cell, Cutaneous 143Uveal Melanoma 96Skin Neoplasms 96Mycosis Fungoides 95Sezary Syndrome 81Carcinoma, Basal Cell 76Neoplasm Metastasis 68Lymphoma 64Lymphoma, Non-Hodgkin 63Keratosis, Actinic 61Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 57Carcinoma, Renal Cell 55Carcinoma, Non-Small-Cell Lung 54Lymphoma, B-Cell, Marginal Zone 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 52Lymphoma, Follicular 52Hodgkin Disease 52Lymphoma, Large-Cell, Immunoblastic 50Carcinoma, Merkel Cell 50Burkitt Lymphoma 49Brain Neoplasms 46Multiple Myeloma 44Lymphoma, Large-Cell, Anaplastic 41Recurrence 40Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40Breast Neoplasms 40

Interventions

binimetinib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × Dermatologic × Clear all
NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Pfizer

Phase 2 Completed
183 enrolled 35 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
3 enrolled 2 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡